Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I).

##STR00001##

or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein n, x, A, Q.sub.1, Q.sub.2, Z, R, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.

Pharmaceutical compositions of the invention comprise functionalized N,N-dialkylamino phenyl ethers derivatives having a disease-modifying action in the treatment of diseases associated with lysosomal storage dysfunction that include Gaucher's disease, and any disease or condition involving lysosomal storage dysfunction.

Pharmaceutical compositions of the invention comprise functionalized N,N-dialkylamino phenyl ethers derivatives having a disease-modifying action in the treatment of diseases associated with lysosomal storage dysfunction that include Gaucher's disease, and any disease or condition involving lysosomal storage dysfunction.

Methods and devices are disclosed for selective photo-destruction of one chiral enantiomer of a compound using nanostructures by enhancing differential absorption of circularly polarized light by the one chiral enantiomer. Methods and devices are disclosed for selective enrichment of one chiral enantiomer of a compound using nanostructures by enhancing differential absorption of circularly polarized light by the one chiral enantiomer. The nanostructures support optical frequency electric resonances and optical frequency magnetic resonances.

Methods and devices are disclosed for selective photo-destruction of one chiral enantiomer of a compound using nanostructures by enhancing differential absorption of circularly polarized light by the one chiral enantiomer. Methods and devices are disclosed for selective enrichment of one chiral enantiomer of a compound using nanostructures by enhancing differential absorption of circularly polarized light by the one chiral enantiomer. The nanostructures support optical frequency electric resonances and optical frequency magnetic resonances.

Phenoxy acetic acids and phenyl propionic acids and their use in improving mitochondrial energy output in a subject are provided herein. The present compounds are activators of PPAR and may be useful for treating conditions mediated by the same.

Phenoxy acetic acids and phenyl propionic acids and their use in improving mitochondrial energy output in a subject are provided herein. The present compounds are activators of PPAR and may be useful for treating conditions mediated by the same.

A quaternary ammonium compound of formula (I): (I) wherein R.sup.0, R.sup.1, R.sup.2 and R.sup.3 is each independently an optionally substituted hydrocarbyl group, X is a linking group, R.sup.4 is an optionally substituted alkylene group, R5 is hydrogen or an optionally substituted alkyl, alkenyl or aryl group, and n is 0 or a positive integer, provided that n is not 0 when R5 is hydrogen.

##STR00001##

Pharmaceutical compositions of the invention comprise functionalized N,N-dialkylamino phenyl ethers derivatives having a disease-modifying action in the treatment of diseases associated with lysosomal storage dysfunction that include Gaucher's disease, and any disease or condition involving lysosomal storage dysfunction.

Pharmaceutical compositions of the invention comprise functionalized N,N-dialkylamino phenyl ethers derivatives having a disease-modifying action in the treatment of diseases associated with lysosomal storage dysfunction that include Gaucher's disease, and any disease or condition involving lysosomal storage dysfunction.